Cargando…

Persisting with prevention: The importance of adherence for HIV prevention

BACKGROUND: Only four out of 31 completed randomized controlled trials (RCTs) of HIV prevention strategies against sexual transmission have shown significant efficacy. Poor adherence may have contributed to the lack of effect in some of these trials. In this paper we explore the impact of various le...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Helen A, Wasserheit, Judith N, Barnabas, Ruanne V, Hayes, Richard J, Abu-Raddad, Laith J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2507711/
https://www.ncbi.nlm.nih.gov/pubmed/18620578
http://dx.doi.org/10.1186/1742-7622-5-8
_version_ 1782158390289498112
author Weiss, Helen A
Wasserheit, Judith N
Barnabas, Ruanne V
Hayes, Richard J
Abu-Raddad, Laith J
author_facet Weiss, Helen A
Wasserheit, Judith N
Barnabas, Ruanne V
Hayes, Richard J
Abu-Raddad, Laith J
author_sort Weiss, Helen A
collection PubMed
description BACKGROUND: Only four out of 31 completed randomized controlled trials (RCTs) of HIV prevention strategies against sexual transmission have shown significant efficacy. Poor adherence may have contributed to the lack of effect in some of these trials. In this paper we explore the impact of various levels of adherence on measured efficacy within an RCT. ANALYSIS: We used simple quantitative methods to illustrate the impact of various levels of adherence on measured efficacy by assuming a uniform population in terms of sexual behavior and the binomial model for the transmission probability per partnership. At 100% adherence the measured efficacy within an RCT is a reasonable approximation of the true biological efficacy. However, as adherence levels fall, the efficacy measured within a trial substantially under-estimates the true biological efficacy. For example, at 60% adherence, the measured efficacy can be less than half of the true biological efficacy. CONCLUSION: Poor adherence during a trial can substantially reduce the power to detect an effect, and improved methods of achieving and maintaining high adherence within trials are needed. There are currently 12 ongoing HIV prevention trials, all but one of which require ongoing user-adherence. Attention must be given to methods of maximizing adherence when piloting and designing RCTs and HIV prevention programmes.
format Text
id pubmed-2507711
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25077112008-08-12 Persisting with prevention: The importance of adherence for HIV prevention Weiss, Helen A Wasserheit, Judith N Barnabas, Ruanne V Hayes, Richard J Abu-Raddad, Laith J Emerg Themes Epidemiol Analytic Perspective BACKGROUND: Only four out of 31 completed randomized controlled trials (RCTs) of HIV prevention strategies against sexual transmission have shown significant efficacy. Poor adherence may have contributed to the lack of effect in some of these trials. In this paper we explore the impact of various levels of adherence on measured efficacy within an RCT. ANALYSIS: We used simple quantitative methods to illustrate the impact of various levels of adherence on measured efficacy by assuming a uniform population in terms of sexual behavior and the binomial model for the transmission probability per partnership. At 100% adherence the measured efficacy within an RCT is a reasonable approximation of the true biological efficacy. However, as adherence levels fall, the efficacy measured within a trial substantially under-estimates the true biological efficacy. For example, at 60% adherence, the measured efficacy can be less than half of the true biological efficacy. CONCLUSION: Poor adherence during a trial can substantially reduce the power to detect an effect, and improved methods of achieving and maintaining high adherence within trials are needed. There are currently 12 ongoing HIV prevention trials, all but one of which require ongoing user-adherence. Attention must be given to methods of maximizing adherence when piloting and designing RCTs and HIV prevention programmes. BioMed Central 2008-07-11 /pmc/articles/PMC2507711/ /pubmed/18620578 http://dx.doi.org/10.1186/1742-7622-5-8 Text en Copyright © 2008 Weiss et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Analytic Perspective
Weiss, Helen A
Wasserheit, Judith N
Barnabas, Ruanne V
Hayes, Richard J
Abu-Raddad, Laith J
Persisting with prevention: The importance of adherence for HIV prevention
title Persisting with prevention: The importance of adherence for HIV prevention
title_full Persisting with prevention: The importance of adherence for HIV prevention
title_fullStr Persisting with prevention: The importance of adherence for HIV prevention
title_full_unstemmed Persisting with prevention: The importance of adherence for HIV prevention
title_short Persisting with prevention: The importance of adherence for HIV prevention
title_sort persisting with prevention: the importance of adherence for hiv prevention
topic Analytic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2507711/
https://www.ncbi.nlm.nih.gov/pubmed/18620578
http://dx.doi.org/10.1186/1742-7622-5-8
work_keys_str_mv AT weisshelena persistingwithpreventiontheimportanceofadherenceforhivprevention
AT wasserheitjudithn persistingwithpreventiontheimportanceofadherenceforhivprevention
AT barnabasruannev persistingwithpreventiontheimportanceofadherenceforhivprevention
AT hayesrichardj persistingwithpreventiontheimportanceofadherenceforhivprevention
AT aburaddadlaithj persistingwithpreventiontheimportanceofadherenceforhivprevention